Cipla : Q1 FY24 Investor Presentation

26th July 2023
(1) BSE Ltd.	(2) National Stock Exchange of India Ltd.
Listing Department	Listing Department
Phiroze Jeejeebhoy Towers	Exchange Plaza, 5th floor
Dalal Street	Plot no. C/1, G Block
Mumbai 400 001	Bandra Kurla Complex
Scrip Code: 500087	Bandra (East), Mumbai - 400 051
	Scrip Code: CIPLA
(3) SOCIETE DE LA BOURSE DE
LUXEMBERG
Societe Anonyme
35A Boulevard Joseph II
L-1840 Luxembourg

Sub: Investor Presentation

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing herewith the Investor Presentation dated 26th July 2023.

Kindly take the above information on record.

Thanking you,

Yours faithfully, For Cipla Limited

RAJENDRA KUMAR CHOPRA

Rajendra Chopra Company Secretary

Encl: as above

Digitally signed by

RAJENDRA KUMAR CHOPRA Date: 2023.07.26 15:10:34 +05'30'

Prepared by: Pavankumar Yadav

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India

P [phone] F [phone] Wwww.cipla.com [e-mail] Identity Number L24239MH1935PLC002380

Investor Presentation

Q1FY24

26-07-2023

1

DISCLAIMER

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.

The investor presentation is not intended to endorse, advertise, promote or recommend the use of any products listed in it which are for representation purpose only, some of which are reference listed drugs of which the Company has approved, under approval or under development generic equivalents. The prefixes "g" and "generic" used interchangeably indicate the generic versions of the named brand drugs.

Information relating to any medical products or medical devices contained herein is provided by Cipla for general information purposes only. Information on any of the medical products or medical devices may vary from country-to-country. A reference to a medical product or a medical device does not imply that such medical product or medical device is available in your country. The commercial availability of the medical products or medical devices listed herein in your country is dependent on the validity and status of existing patents and/or marketing authorizations related to each. An independent enquiry regarding the availability of each medical products or medical device should be made for each individual country.

The product information contained herein is not intended to provide complete medical information, and is not intended to be used as an alternative to consulting with qualified doctors or health care professionals.

Nothing contained herein should be construed as giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or action. It is important to only rely on the advice of a health care professional.

2

Q1FY24 : Revenue up YoY by 18%; Margin expansion YoY by 230+ bps

Stellar Performance across all markets

KEY HIGHLIGHTS

Global Revenue

INR 6,329 Cr 18%

Reported

YoY growth

EBITDA Margin

23.6%	233 bps
	(YoY)

31%

Reported

YoY growth

R&D Investment1

5.5%	27%
of overall	YoY growth
revenue

BUSINESS PERFORMANCE

One-India

INR 2,772 Cr 12%

YoY growth in INR terms

Market beating growth continues in branded prescription business

North America

$ 222 Mn 43%

YoY growth in $ terms

Highest ever quarterly revenue,

led by key assets

South Africa Private

Market

ZAR 939 Mn 13%

YoY growth in ZAR Terms

Robust growth in prescription and

OTC business

International Markets

$ 95 Mn 2%

YoY growth in $ terms

Double digit secondary growth

across key DTM2s

1. Opex including depreciation | 2. DTM - Direct to market	3

Financial Performance - Q1FY24

Revenues	INR 6,329 Cr
	Revenue1 Break-up
API, 2%	Others, 1%
International
Markets,
12%
SAGA,
12%		India, 44%

North America, 29%

	EBITDA	INR 1,494 Cr
		Q1FY24 (Consolidated)
				Actuals	vs Q1 FY23
				(INR Cr)
	Total Revenue from		6,329	17.7%
	Operations
	EBITDA			1,494	30.7%
	EBITDA %			23.6%	233 bps
	PAT			996	45.1%
	PAT %			15.7%	296 bps

R&D2	5.5% of revenue	27%
YoY growth

1. India includes Branded Prescription, Trade Generics and Consumer Health; SAGA includes South Africa, Sub-Saharan Africa, QCIL and Cipla Global Access; International Markets include	4
Emerging Markets and Europe | Figures have been rounded-off|2. Opex including depreciation